IDEAYA Biosciences (FRA:30J) ROCE % : -52.19% (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is IDEAYA Biosciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. IDEAYA Biosciences's annualized ROCE % for the quarter that ended in Dec. 2024 was -52.19%.

IDEAYA Biosciences ROCE % Historical Data

The historical data trend for IDEAYA Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDEAYA Biosciences ROCE % Chart

IDEAYA Biosciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-18.81

-17.41

-18.62

-27.19

-39.03

IDEAYA Biosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-29.38	-26.22	-27.92	-24.76	-52.19

IDEAYA Biosciences ROCE % Calculation

IDEAYA Biosciences's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-312.261	/	( ( (595.423 - 24.852)	+	(1073.507 - 43.998) )	/ 2 )
	=	-312.261	/	( (570.571	+	1029.509)	/ 2 )
	=	-312.261	/	800.04
	=	-39.03 %

IDEAYA Biosciences's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-550.608	/	( ( (1117.126 - 36.634)	+	(1073.507 - 43.998) )	/ 2 )
	=	-550.608	/	( ( 1080.492	+	1029.509 )	/ 2 )
	=	-550.608	/	1055.0005
	=	-52.19 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

IDEAYA Biosciences (FRA:30J) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

IDEAYA Biosciences ROCE % Related Terms

Thank you for viewing the detailed overview of IDEAYA Biosciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

IDEAYA Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IDEAYA Biosciences Inc (FRA:30J) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

IDYA:USA

Address

5000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.ideayabio.com

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

IDEAYA Biosciences Headlines

No Headlines